GSK acquires RAPT Therapeutics

GSK agreed to acquire RAPT Therapeutics. Reported deal value: $2.2B. Status: Pending. Sector: biopharmaceutical. Target headquarters context: South San Francisco, California, United States.

This page summarizes publicly available information about the transaction as of 2026-01-21. Figures and status may change as filings and press coverage update.

Brian Wong, President and Chief Executive Officer, Rapt Therapeutics , said: This transaction has the potential to provide access to the global development and commercialisation capabilities, resources and infrastructure that GSK has to offer and ultimately bring added value to our pipeline, patients and stockholders